Characteristics of study participants
| Characteristic* | Treatment group; no. of patients† | |
|---|---|---|
| Levomepromazine (n = 19) | Chlorpromazine (n = 19) | |
| Mean age, (SD) [and range], yr | 38.5 (9.6) [20–54] | 39.4 (8.8) [26–54] |
| Male:female ratio | 12:7 | 12:7 |
| Type of schizophrenia diagnosed | ||
| Paranoid | 12 | 7 |
| Disorganized | 3 | 8 |
| Undifferentiated | 4 | 4 |
| Mean age of onset of illness, (SD) [and range], yr | 20.4 (5.2) [13–32] | 20.2 (4.1) [15–28] |
| Mean duration of illness, (SD) [and range], yr | 18.7 (9.3) [5–34] | 19.3 (7.9) [9–34] |
| Mean no. of hospital admissions, (SD) [and range] | 8.8 (6.2) [2–23] | 11.2 (8.1) [3–40] |
| Three treatment periods completed within | ||
| ≤5 yr of entry into baseline | 16 | 15 |
| > 5 yr of entry into baseline | 3 | 4 |
| Earlier history | ||
| Clozapine treatment | 3 | 3 |
| Risperidone treatment | 5 | 6 |
| Mean duration of current stay in hospital, (SD) [and range], wk | 232 (200) [22–680] | 329 (412) [12–1605] |